Neuroendocrine Carcinoma Metastatic study: [18F]FluorThanatrace
Official title FTT PET/CT in Pancreatic Neuroendocrine Tumors
ClinicalTrials.gov ID: NCT07114939
What this study is testing
What is [18F]FluorThanatrace?
An investigational radioactive imaging agent being studied for detecting pancreatic neuroendocrine tumors.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how much of the protein PARP‑1 is present in these tumors by using a special PET imaging agent called [18F]FluorThanatrace.
- Who it's for
- Adults who have metastatic pancreatic neuroendocrine tumors.
- What's involved
- Participants will receive a small dose of the tracer and then have a whole‑body PET‑CT scan that starts right before the injection and continues for about 60 minutes. A second scan may be done up to 90 minutes later if the investigator decides.
- Time commitment
- The study involves a single imaging visit that lasts roughly two hours.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must be ≥ 18 years of age.
- Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic neuroendocrine tumor.
- Have at least one lesion on clinical imaging (e.g. CT/MRI/PET/CT/ultrasound) that is ≥ 1.5 cm in size.
- Patients may be receiving any form of treatment or not be undergoing current treatment.
- Willing to consent to use of tumor tissue (fresh frozen and/or clinical pathology specimens) collected as part of another study or biobank collection...
You likely can't join if
- Patients who have received liver directed therapy that treated all of their disease but whom have not yet had disease progression, per medical record...
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Females who are pregnant or breastfeeding will not be eligible for this study
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician...
See the full eligibility criteria
- Patients must be ≥ 18 years of age.
- Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic neuroendocrine tumor.
- Have at least one lesion on clinical imaging (e.g. CT/MRI/PET/CT/ultrasound) that is ≥ 1.5 cm in size.
- Patients may be receiving any form of treatment or not be undergoing current treatment.
- Willing to consent to use of tumor tissue (fresh frozen and/or clinical pathology specimens) collected as part of another study or biobank collection or clinical procedure.
- Must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to...
- Patients who have received liver directed therapy that treated all of their disease but whom have not yet had disease progression, per medical record review.
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection.
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or...
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.